CN107531779B - 血清型交叉反应性登革热中和抗体和其用途 - Google Patents

血清型交叉反应性登革热中和抗体和其用途 Download PDF

Info

Publication number
CN107531779B
CN107531779B CN201680027752.4A CN201680027752A CN107531779B CN 107531779 B CN107531779 B CN 107531779B CN 201680027752 A CN201680027752 A CN 201680027752A CN 107531779 B CN107531779 B CN 107531779B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
seq
denv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680027752.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107531779A (zh
Inventor
汪正一
K·芬克
P·玛卡里
R·泽斯特
许美慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
National University of Singapore
Original Assignee
Agency for Science Technology and Research Singapore
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore, National University of Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CN107531779A publication Critical patent/CN107531779A/zh
Application granted granted Critical
Publication of CN107531779B publication Critical patent/CN107531779B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680027752.4A 2015-03-17 2016-03-17 血清型交叉反应性登革热中和抗体和其用途 Active CN107531779B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201502068V 2015-03-17
SG10201502068V 2015-03-17
PCT/SG2016/050124 WO2016148653A1 (en) 2015-03-17 2016-03-17 A serotype cross-reactive, dengue neutralizing antibody and uses thereof

Publications (2)

Publication Number Publication Date
CN107531779A CN107531779A (zh) 2018-01-02
CN107531779B true CN107531779B (zh) 2021-04-13

Family

ID=56920185

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680027752.4A Active CN107531779B (zh) 2015-03-17 2016-03-17 血清型交叉反应性登革热中和抗体和其用途

Country Status (6)

Country Link
US (1) US10316078B2 (https=)
EP (1) EP3271390B1 (https=)
JP (1) JP6957355B2 (https=)
CN (1) CN107531779B (https=)
SG (1) SG11201707592TA (https=)
WO (1) WO2016148653A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
CA3093729A1 (en) * 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US10526398B2 (en) * 2018-06-12 2020-01-07 National Defense Medical Center Anti-dengue virus antibodies and applications thereof
TWI737918B (zh) * 2018-06-12 2021-09-01 國防醫學院 抗登革病毒抗體及其應用
CN109929033B (zh) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 一种特异性结合四种血清型登革病毒的人源抗体
CN115697392B (zh) * 2020-06-28 2026-03-13 神州细胞工程有限公司 一种降低病毒ade效应的方法
WO2022163845A1 (ja) * 2021-01-31 2022-08-04 株式会社バランス・イースト 検査システム、検査方法、プログラム、およびコンピュータが読み取り可能な記憶媒体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753418B2 (en) 2000-10-05 2004-06-22 Case Western Reserve University Suppressors of human breast cancer cell growth
US8470976B2 (en) 2006-06-17 2013-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting macromolecules into the nucleus
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
MX2011003588A (es) * 2008-10-13 2011-10-14 Inst Research In Biomedicine Anticuerpos neutralizadores del virus del dengue y uso de los mismos.
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
US9212217B2 (en) * 2014-02-11 2015-12-15 Visterra, Inc. Antibody molecules to dengue virus and uses thereof

Also Published As

Publication number Publication date
EP3271390A4 (en) 2018-08-08
CN107531779A (zh) 2018-01-02
SG11201707592TA (en) 2017-10-30
EP3271390B1 (en) 2023-09-27
JP6957355B2 (ja) 2021-11-02
WO2016148653A1 (en) 2016-09-22
US10316078B2 (en) 2019-06-11
EP3271390A1 (en) 2018-01-24
JP2018514193A (ja) 2018-06-07
US20180072798A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
CN107531779B (zh) 血清型交叉反应性登革热中和抗体和其用途
CN109563157B (zh) 特异性地结合至寨卡病毒表位的新型抗体和其用途
JP6483337B2 (ja) デングウイルス血清型１のｅタンパク質に対して特異性を有するヒトモノクローナル抗体およびその使用
KR20160117608A (ko) 뎅기열 바이러스에 대한 항체 분자 및 그의 용도
CN106589116B (zh) 一种黄病毒人源单克隆抗体及应用
KR20230152062A (ko) 항tslp 항체를 포함하는 의약 조성물
KR20200042499A (ko) 지카 바이러스 에피토프에 특이적으로 결합하는 다중특이적 항체 및 이의 용도
WO2014115893A1 (ja) ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
CN110343174B (zh) 一种高亲和力的黄热病毒人源单克隆抗体及其应用
JP2011072248A (ja) 狂犬病ウイルスに対するヒト抗体ならびにその組成物
CN110343173B (zh) 一种高功能活性的黄热病毒人源单克隆抗体及其应用
CN110343172B (zh) 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN107286237B (zh) 一种抗丙型肝炎病毒抗体的获取以及应用
TWI915520B (zh) 含抗tslp抗體的藥物組合物
US20240287160A1 (en) Antibody cocktail for treatment of ebolavirus infections
HK40097033B (zh) 含抗tslp抗体的药物组合物
HK40097033A (zh) 含抗tslp抗体的药物组合物
EA043940B1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
HK40006233A (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
HK40006233B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
HK1190731A (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
HK1190731B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant